Fig. 9. Genomic confirmation of DDX1, hnRNP H2, and hnRNP A2/B1 as targets of 2155-14. (A) Western blot of WM266-4 lysates validates DDX1, hnRNP H2, and hnRNP A2/B1 as binding targets of biotinylated analog of 2155-14, 2529-7. (B) DDX1, hnRNP H2, and hnRNP A2/B1 expression is knocked down by the corresponding siRNAs. (C,D,E) WM266-4 cell viability after treatment with DDX1, hnRNP H2, and hnRNP A2/B1 siRNAs and combinations thereof at concentrations which produced complete knockdown of respective proteins as shown in (B). One-way analysis of variance (ANOVA) was used followed by Dunnett post hoc test. The data shown were the mean ± SD, n=6. ***** - p<0.0001, *** - p<0.001, ** - p<0.01, * - p<0.05, ns = no significance. (F) WM266-4 viability time course assay in the presence of dose response of 2155-14. Please note similarity of time dependent loss of viability of WM266-4 starting at 48 h in the presence of siRNAs and 2155-14.